Table 3.
Occurrence Rate of Toxicities Between Two Groups
| Adverse Events | Study | Control | p Value |
|---|---|---|---|
| Gastrointestinal toxicities | |||
| Diarrhea | 0.002 | ||
| Yes | 11 (5.4%) | 29 (14.6%) | |
| No | 193 (94.6%) | 170 (85.4%) | |
| Nausea | 0.005 | ||
| Yes | 55 (27.0%) | 80 (40.2%) | |
| No | 149 (73.0%) | 119 (59.8%) | |
| Vomiting | 0.205 | ||
| Yes | 23 (11.3%) | 31 (15.6%) | |
| No | 181 (88.7%) | 168 (84.4%) | |
| Hepatic toxicities | |||
| Increased SGOT level | 0.202 | ||
| Yes | 36 (17.6%) | 26 (13.1%) | |
| No | 168 (82.4%) | 173 (86.9%) | |
| Increased SGPT level | 0.737 | ||
| Yes | 29 (14.2%) | 26 (13.1%) | |
| No | 175 (85.8%) | 173 (86.9%) | |
| Hematologic toxicities | |||
| Leukopenia | 0.015 | ||
| Yes | 52 (25.5%) | 73 (36.7%) | |
| No | 152 (74.5%) | 126 (63.3%) | |
| Anemia | 0.005 | ||
| Yes | 160 (78.4%) | 131 (65.8%) | |
| No | 44 (21.6%) | 68 (34.2%) | |
Abbreviations: SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase.